Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06600178

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG) (STRONG)

Innovative Therapy to Treat Women With Angina With Nonobstructive Coronary Artery Disease (ANOCA) and Coronary Microvascular Disease

Sponsor: University of Virginia

Conditions Angina Patients With Non-obstructive Coronary Artery Disease Coronary Microvascular Disease Coronary Microvascular Dysfunction (CMD)

Interventions Brezavvy 20Mg Oral Tablet Placebo

Updated 3 times since 2024 Last updated: Oct 27, 2025 Started: Jun 27, 2025 Primary completion: Mar 31, 2026 Completion: Oct 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Angina Patients With Non-obstructive Coronary Artery Disease and Coronary Microvascular Disease, this trial is actively recruiting participants. The trial is conducted by University of Virginia and has accumulated 3 data snapshots since 2025. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

3 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Apr 2025 — Nov 2025 [monthly]

Not Yet Recruiting PHASE1
Oct 2024 — Apr 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Virginia

Data source: University of Virginia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Charlottesville, United States